Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2015 - 2024)

Akebia Therapeutics (AKBA) has 10 years of Non-Current Deffered Revenue data on file, last reported at $43.3 million in Q1 2024.

• On a quarterly basis, Non-Current Deffered Revenue changed 0.0% year-over-year to $43.3 million in Q1 2024; TTM through Mar 2024 was $43.3 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $43.3 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q1 2024 stood at $43.3 million, roughly flat from $43.3 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for AKBA reached as high as $65.4 million in Q1 2022 and fell as low as $16.6 million in Q2 2021.
• Historically, Non-Current Deffered Revenue has averaged $37.3 million across 5 years, with a median of $43.3 million in 2022.
• Across the five-year window, Non-Current Deffered Revenue plunged 54.91% in 2021 and surged 238.65% in 2022, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $25.3 million in 2020, then slipped by 15.27% to $21.5 million in 2021, then soared by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $43.3 million in Q1 2024, $43.3 million in Q4 2023, and $43.3 million in Q3 2023.